Another striking finding was that celecoxib significantly reduced the expression of Wnt5a at both protein and mRNA level accompanied with protective effect of celecoxib on the development of T2DM-related NASH in the T2DM-NASH-Cele group. The gene discussed is WNT5A; the disease is metabolic dysfunction-associated steatohepatitis.